Mustafa Guzel
35Patents
8h-index
43Co-inventors
75Inventor score
Filing activity: Oct 6, 2003 → Apr 3, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7384967B2 | Aryl carbonyl derivatives as therapeutic agents | Chemistry; Metallurgy | 149 | Expired |
| US7541373B2 | Aryl carbonyl derivatives as therapeutic agents | Chemistry; Metallurgy | 123 | Active |
| US7459472B2 | Aryl and heteroaryl compounds, compositions, and methods of use | Chemistry; Metallurgy | 93 | Expired |
| USRE45670E1 | Aryl carbonyl derivatives as therapeutic agents | General | 33 | Active |
| US7897628B2 | Aryl carbonyl derivatives as therapeutic agents | Chemistry; Metallurgy | 14 | Active |
| US8759535B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | Chemistry; Metallurgy | 12 | Active |
| US10287284B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | Chemistry; Metallurgy | 12 | Active |
| US7906507B2 | Oxadiazoanthracene compounds for the treatment of diabetes | Chemistry; Metallurgy | 9 | Active |
| US8329715B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | Emerging Cross-Sectional Technologies | 8 | Active |
| US7727983B2 | Oxadiazoanthracene compounds for the treatment of diabetes | Chemistry; Metallurgy | 7 | Active |
| US7790714B2 | Oxadiazoanthracene compounds for the treatment of diabetes | Chemistry; Metallurgy | 7 | Active |
| US9393245B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | Emerging Cross-Sectional Technologies | 5 | Active |
| US8063081B2 | Aryl carbonyl derivatives as therapeutic agents | Chemistry; Metallurgy | 5 | Active |
| US8524708B2 | Oxadiazoanthracene compounds for the treatment of diabetes | Chemistry; Metallurgy | 4 | Active |
| US8703766B2 | Oxadiazoanthracene compounds for the treatment of diabetes | Chemistry; Metallurgy | 4 | Active |
| US9120813B2 | Oxadiazoanthracene compounds for the treatment of diabetes | Chemistry; Metallurgy | 3 | Active |
| US10030011B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | Chemistry; Metallurgy | 2 | Active |
| US10889580B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | Chemistry; Metallurgy | 2 | Active |
| US10570126B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | Chemistry; Metallurgy | 2 | Active |
| US11130753B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | Chemistry; Metallurgy | 2 | Active |
| US8933222B2 | Oxadiazoanthracene compounds for the treatment of diabetes | Chemistry; Metallurgy | 2 | Active |
| US11649230B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | Chemistry; Metallurgy | 1 | Active |
| US8987295B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | Chemistry; Metallurgy | 1 | Active |
| US10568888B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | Emerging Cross-Sectional Technologies | 1 | Active |
| US9175003B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.